Palo Alto Investors

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.

Lab­cyte Inc. is a lab­o­ra­tory instru­men­ta­tion com­pany with a novel approach to dis­pens­ing small vol­umes of liq­uids for life sci­ences appli­ca­tions. The company's acoustic dis­pens­ing tech­nol­ogy uses a focused beam of acoustic energy to eject nanoliter-​​scale droplets of fluid from one plate to another, with high accu­racy at low vol­umes and reduced con­sum­ables costs. In addi­tion to DBL Investors, investors include Alloy Ven­tures, Abing­worth, New Leaf Ven­ture Part­ners, and Cross Atlantic Partners. Labcyte was founded in 2000 and is based in San Jose, California, United States.

As of June 13, 2005, Speedera Networks, Inc. was acquired by Akamai Technologies Inc. Speedera Networks, Inc. provides distributed application hosting and content delivery services for organizations in both industry and government sectors. Its family of on-demand services solves the performance, scalability, availability, and security problems of distributed applications and Web sites. The company was founded in 1999 and is headquartered in Santa Clara, California.

Fisker Automotive was an American company known for producing the Fisker Karma, which was one of the world's first production luxury plug-in hybrid electric vehicles. It debuted at the 2008 North American International Auto Show, and the first deliveries were in 2011. Production of the Fisker Karma was suspended in November 2012 due to the bankruptcy of its battery supplier A123 Systems, with about 2,450 Karmas built since 2011 and over 2000 cars sold worldwide. In February 2014, Fisker Automotive's Karma vehicle design, tooling, and a manufacturing facility in Delaware were purchased by Chinese auto parts conglomerate Wanxiang Group.

Provider of carrier-class broadband wireless equipment and networking, wireless voip and other wireless applications

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Gemfire Corporation combines an entrepreneurial atmosphere with an extensive technology base. Founded in 1995, Gemfire specializes in applying planar semi-conductor-type processing technology to create optical solutions for system integrators, through an innovative new family of high-performance telecom and specialty components. Currently, the company has primary operations in Livingston, Scotland (near Edinburgh), as well as aerospace support operations (and additional telecom manufacturing capabilities) in Fremont, California.

Fisker Automotive was an American company known for producing the Fisker Karma, which was one of the world's first production luxury plug-in hybrid electric vehicles. It debuted at the 2008 North American International Auto Show, and the first deliveries were in 2011. Production of the Fisker Karma was suspended in November 2012 due to the bankruptcy of its battery supplier A123 Systems, with about 2,450 Karmas built since 2011 and over 2000 cars sold worldwide. In February 2014, Fisker Automotive's Karma vehicle design, tooling, and a manufacturing facility in Delaware were purchased by Chinese auto parts conglomerate Wanxiang Group.

Fisker Automotive was an American company known for producing the Fisker Karma, which was one of the world's first production luxury plug-in hybrid electric vehicles. It debuted at the 2008 North American International Auto Show, and the first deliveries were in 2011. Production of the Fisker Karma was suspended in November 2012 due to the bankruptcy of its battery supplier A123 Systems, with about 2,450 Karmas built since 2011 and over 2000 cars sold worldwide. In February 2014, Fisker Automotive's Karma vehicle design, tooling, and a manufacturing facility in Delaware were purchased by Chinese auto parts conglomerate Wanxiang Group.

Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.

NewLeaf Symbiotics develops and commercializes the bacteria found in Pink Pigmented Facultative Methylotrophs. NewLeaf Symbiotics has also filed its own related patents and is actively developing new technologies related to PPFMs. The Company is engaged in laboratory, greenhouse, and field product trials and expects to commercialize and license products beginning in 2014.

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

Gilgamesh Pharmaceuticals provides medicines for psychedelic, novel psychotropic drugs, depression, anxiety, and stress-related disorders. The company's drugs treat neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders, enabling patients suffering from central nervous system disorders to recover with ease. They developing innovative new chemical entities (NCE’s) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise.

Mercator MedSystems, Inc., a medical technology company, develops catheter-guided microfluid injection systems for site-specific delivery of therapeutic agents directly across various blood vessels. The company offers Cricket and Bullfrog micro-infusion catheters, which are designed to inject therapeutic agents directly and non-systemically through blood vessel walls into deep tissues. It offers products for the treatment of blood vessel restenosis caused by inflammation after vascular injury; micro-infusion devices to infuse drugs, genes, and cells without material loss in viability or potency; inflammation and restenosis treatment for peripheral artery disease; and micro-infusion catheter for the treatment of neointimal hyperplasia associated with stenotic dialysis access failure. The company’s products are used in various therapies, such as treatments for plaque stabilization in diseased vessels, anti-tumor drugs, growth factors to stimulate cell division, and stem cell transplantation and gene therapies. Its technology also enables the commercialization of novel therapeutics for other vascular diseases, hypertension, oncology, and regenerative medicine. Mercator MedSystems, Inc. was formerly known as Endobionics, Inc. The company was founded in 1999 and is based in Emeryville, California.

Commercial Center of 19000 Square Meters in Las Vegas and a Large Target Anchor Store comprises a commercial property and a retail store. The asset is located in the United States.

NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.

Provider of carrier-class broadband wireless equipment and networking, wireless voip and other wireless applications

Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Provider of carrier-class broadband wireless equipment and networking, wireless voip and other wireless applications

Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.

Fisker Automotive was an American company known for producing the Fisker Karma, which was one of the world's first production luxury plug-in hybrid electric vehicles. It debuted at the 2008 North American International Auto Show, and the first deliveries were in 2011. Production of the Fisker Karma was suspended in November 2012 due to the bankruptcy of its battery supplier A123 Systems, with about 2,450 Karmas built since 2011 and over 2000 cars sold worldwide. In February 2014, Fisker Automotive's Karma vehicle design, tooling, and a manufacturing facility in Delaware were purchased by Chinese auto parts conglomerate Wanxiang Group.

Paracor Medical is an innovative medical device company focused on providing unique, technology-driven solutions for the treatment of heart failure. Founded in 1999, Paracor was established to pursue new and innovative ways to treat heart failure (HF) that would not require the patient to undergo open chest surgery. Paracor engineers recognized that a mechanical approach to reducing the workload of a failing, diseased heart muscle could be a new and effective solution.

Lab­cyte Inc. is a lab­o­ra­tory instru­men­ta­tion com­pany with a novel approach to dis­pens­ing small vol­umes of liq­uids for life sci­ences appli­ca­tions. The company's acoustic dis­pens­ing tech­nol­ogy uses a focused beam of acoustic energy to eject nanoliter-​​scale droplets of fluid from one plate to another, with high accu­racy at low vol­umes and reduced con­sum­ables costs. In addi­tion to DBL Investors, investors include Alloy Ven­tures, Abing­worth, New Leaf Ven­ture Part­ners, and Cross Atlantic Partners. Labcyte was founded in 2000 and is based in San Jose, California, United States.

Building of 12000 Square Meters in North Las Vegas comprises a commercial center building and is located in the United States.

FlowMedica a medical device company, produces intravascular systems for implementing Targeted Renal Therapy. The company offers Benephit CV Infusion System that provides physician-specified therapeutic agents directly into the renal arteries through an infusion catheter while allowing simultaneous coronary procedures through a single vessel access site in the femoral artery; and Benephit XTMini Infusion System that allows for bilateral infusion to the kidneys in patients with smaller vascular anatomies.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.

As of March 9, 2020, Menlo Therapeutics Inc. was acquired by Foamix Pharmaceuticals Ltd., in a reverse merger transaction. Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.

Peak Bio is a Biopharmaceutical company that focuses on the drug development to treat Oncology and Inflammatory diseases.